![]() Pleurodynia Treatment Market Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Diagnosis (Blood test, Culture test, X-ray), By Treatment (Analgesics or Painkillers, Immunoglobulin), By Mode of Administration (Oral, Injections or infusion), By End-User (Hospitals, Pharmacy, Others), By Region & Competition, 2020-2030F
Global Pleurodynia Treatment Market was valued at USD 143.55 Million in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2030. The Global Pleurod... もっと見る
SummaryGlobal Pleurodynia Treatment Market was valued at USD 143.55 Million in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2030. The Global Pleurodynia Treatment Market represents a rapidly evolving segment within the healthcare industry, driven by advancements in diagnostic technology and increasing disease prevalence. Pleurodynia, commonly referred to as "Devil’s Grip," is a viral infection primarily caused by enteroviruses, notably Coxsackievirus, and is characterized by acute chest pain and myalgia, predominantly affecting children and young adults.Market growth is underpinned by significant developments in molecular diagnostics, particularly Polymerase Chain Reaction (PCR) and Next-Generation Sequencing (NGS), which have substantially improved diagnostic precision and reduced the time to detection. These innovations enhance early-stage identification and allow for timely intervention, ultimately improving patient outcomes. However, the market faces considerable challenges, primarily due to the lack of targeted antiviral therapies and diagnostic complexities. The absence of specialized treatment options results in a reliance on symptomatic management, limiting the scope of therapeutic advancements. Furthermore, pleurodynia’s clinical presentation often mimics cardiac and respiratory disorders, leading to frequent misdiagnosis and delayed or inappropriate treatment. Despite these hurdles, the global pleurodynia treatment market is positioned for sustained growth, fueled by rising incidence rates and continued investment in diagnostic research. Addressing treatment gaps and refining diagnostic protocols will be critical to unlocking the market’s full potential and enhancing patient care. Key Market Drivers Advancements in Medical Research and Technology In recent years, the healthcare industry has experienced an unprecedented surge in medical research and technological advancements. These innovations have played a pivotal role in driving the growth of the Global Pleurodynia Treatment Market. Cutting-edge diagnostic tools and therapeutic options have been developed, significantly enhancing the management of pleurodynia. One notable advancement is the utilization of molecular diagnostic techniques, such as Polymerase Chain Reaction (PCR) tests. These tests have revolutionized the accuracy and speed of pleurodynia diagnosis. By detecting the viral RNA in patient samples, PCR tests provide rapid and precise results, enabling healthcare professionals to initiate treatment promptly. NGS has also emerged as a game-changer in pleurodynia diagnosis and research. This high-throughput sequencing technology allows for the comprehensive analysis of viral genomes, aiding in the understanding of pleurodynia strains and their genetic variations. Such insights are invaluable for the development of targeted treatments. Key Market Challenges Limited Awareness and Misdiagnosis One of the primary challenges hindering the growth of the Global Pleurodynia Treatment Market is the limited awareness among the general population. Pleurodynia, often referred to as "Devil's Grip," is a relatively uncommon viral infection. Many individuals may not recognize its symptoms, which can mimic other, more common ailments. This lack of awareness results in delayed diagnosis and treatment, impacting market growth. The symptoms of pleurodynia, including severe chest pain and muscle aches, overlap with those of other respiratory and musculoskeletal conditions. Healthcare professionals may misdiagnose pleurodynia as conditions like pneumonia or muscular strain, leading to inappropriate treatment. Accurate and timely diagnosis is crucial for the effective management of pleurodynia, and misdiagnosis can slow down market expansion. Key Market Trends Advancements in Diagnostic Technologies One significant trend in the Global Pleurodynia Treatment Market is the rapid advancement of diagnostic technologies. Molecular diagnostic techniques, such as Polymerase Chain Reaction (PCR) and next-generation sequencing (NGS), have gained prominence. These techniques enable healthcare professionals to detect pleurodynia with higher accuracy and speed by identifying viral RNA in patient samples. The adoption of these cutting-edge diagnostic tools is improving the efficiency of pleurodynia diagnosis and facilitating early treatment initiation. Another notable trend is the development of point-of-care testing for pleurodynia. Point-of-care tests provide rapid results at the patient's bedside or in outpatient settings. These tests are particularly beneficial in regions with limited access to advanced healthcare facilities. The availability of point-of-care tests is expected to enhance the early detection and management of pleurodynia. Key Market Players • Bristol-Myers Squibb Co • F. Hoffmann-La Roche Ltd • Pfizer Inc • Sanofi SA • Johnson & Johnson • Merck & Co Inc. • GlaxoSmithKline PLC • Reckitt Benckiser PLC • Bayer AG • Novartis AG Report Scope: In this report, the Global Pleurodynia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: • Pleurodynia Treatment Market, By Diagnosis: o Blood test o Culture test o X-ray • Pleurodynia Treatment Market, By Treatment: o Analgesics or Painkillers o Immunoglobulin • Pleurodynia Treatment Market, By Mode of Administration: o Oral o Injections or infusion • Pleurodynia Treatment Market, By End-User: o Hospitals o Pharmacy o Others • Pleurodynia Treatment Market, By Region: o North America § United States § Canada § Mexico o Europe § France § United Kingdom § Italy § Germany § Spain o Asia-Pacific § China § India § Japan § Australia § South Korea o South America § Brazil § Argentina § Colombia o Middle East & Africa § South Africa § Saudi Arabia § UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Pleurodynia Treatment Market. Available Customizations: Global Pleurodynia Treatment market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information • Detailed analysis and profiling of additional market players (up to five). Table of Contents1. Product Overview1.1. Market Definition 1.2. Scope of the Market 1.2.1. Markets Covered 1.2.2. Years Considered for Study 1.2.3. Key Market Segmentations 2. Research Methodology 2.1. Objective of the Study 2.2. Baseline Methodology 2.3. Key Industry Partners 2.4. Major Association and Secondary Sources 2.5. Forecasting Methodology 2.6. Data Triangulation & Validation 2.7. Assumptions and Limitations 3. Executive Summary 3.1. Overview of the Market 3.2. Overview of Key Market Segmentations 3.3. Overview of Key Market Players 3.4. Overview of Key Regions/Countries 3.5. Overview of Market Drivers, Challenges, Trends 4. Voice of Customer 5. Pleurodynia Treatment Market Outlook 5.1. Market Size & Forecast 5.1.1. By Value 5.2. Market Share & Forecast 5.2.1. By Diagnosis (Blood test, Culture test, X-ray) 5.2.2. By Treatment (Analgesics or Painkillers, Immunoglobulin) 5.2.3. By Mode of Administration (Oral, Injections or infusion) 5.2.4. By End-User (Hospitals, Pharmacy, Others) 5.2.5. By Region 5.2.6. By Company (2024) 5.3. Market Map 6. North America Pleurodynia Treatment Market Outlook 6.1. Market Size & Forecast 6.1.1. By Value 6.2. Market Share & Forecast 6.2.1. By Diagnosis 6.2.2. By Treatment 6.2.3. By Mode of Administration 6.2.4. By End User 6.2.5. By Country 6.3. North America: Country Analysis 6.3.1. United States Pleurodynia Treatment Market Outlook 6.3.1.1. Market Size & Forecast 6.3.1.1.1. By Value 6.3.1.2. Market Share & Forecast 6.3.1.2.1. By Diagnosis 6.3.1.2.2. By Treatment 6.3.1.2.3. By Mode of Administration 6.3.1.2.4. By End User 6.3.2. Canada Pleurodynia Treatment Market Outlook 6.3.2.1. Market Size & Forecast 6.3.2.1.1. By Value 6.3.2.2. Market Share & Forecast 6.3.2.2.1. By Diagnosis 6.3.2.2.2. By Treatment 6.3.2.2.3. By Mode of Administration 6.3.2.2.4. By End User 6.3.3. Mexico Pleurodynia Treatment Market Outlook 6.3.3.1. Market Size & Forecast 6.3.3.1.1. By Value 6.3.3.2. Market Share & Forecast 6.3.3.2.1. By Diagnosis 6.3.3.2.2. By Treatment 6.3.3.2.3. By Mode of Administration 6.3.3.2.4. By End User 7. Europe Pleurodynia Treatment Market Outlook 7.1. Market Size & Forecast 7.1.1. By Value 7.2. Market Share & Forecast 7.2.1. By Diagnosis 7.2.2. By Treatment 7.2.3. By Mode of Administration 7.2.4. By End User 7.2.5. By Country 7.3. Europe: Country Analysis 7.3.1. Germany Pleurodynia Treatment Market Outlook 7.3.1.1. Market Size & Forecast 7.3.1.1.1. By Value 7.3.1.2. Market Share & Forecast 7.3.1.2.1. By Diagnosis 7.3.1.2.2. By Treatment 7.3.1.2.3. By Mode of Administration 7.3.1.2.4. By End User 7.3.2. United Kingdom Pleurodynia Treatment Market Outlook 7.3.2.1. Market Size & Forecast 7.3.2.1.1. By Value 7.3.2.2. Market Share & Forecast 7.3.2.2.1. By Diagnosis 7.3.2.2.2. By Treatment 7.3.2.2.3. By Mode of Administration 7.3.2.2.4. By End User 7.3.3. Italy Pleurodynia Treatment Market Outlook 7.3.3.1. Market Size & Forecast 7.3.3.1.1. By Value 7.3.3.2. Market Share & Forecast 7.3.3.2.1. By Diagnosis 7.3.3.2.2. By Treatment 7.3.3.2.3. By Mode of Administration 7.3.3.2.4. By End User 7.3.4. France Pleurodynia Treatment Market Outlook 7.3.4.1. Market Size & Forecast 7.3.4.1.1. By Value 7.3.4.2. Market Share & Forecast 7.3.4.2.1. By Diagnosis 7.3.4.2.2. By Treatment 7.3.4.2.3. By Mode of Administration 7.3.4.2.4. By End User 7.3.5. Spain Pleurodynia Treatment Market Outlook 7.3.5.1. Market Size & Forecast 7.3.5.1.1. By Value 7.3.5.2. Market Share & Forecast 7.3.5.2.1. By Diagnosis 7.3.5.2.2. By Treatment 7.3.5.2.3. By Mode of Administration 7.3.5.2.4. By End User 8. Asia-Pacific Pleurodynia Treatment Market Outlook 8.1. Market Size & Forecast 8.1.1. By Value 8.2. Market Share & Forecast 8.2.1. By Diagnosis 8.2.2. By Treatment 8.2.3. By Mode of Administration 8.2.4. By End User 8.2.5. By Country 8.3. Asia-Pacific: Country Analysis 8.3.1. China Pleurodynia Treatment Market Outlook 8.3.1.1. Market Size & Forecast 8.3.1.1.1. By Value 8.3.1.2. Market Share & Forecast 8.3.1.2.1. By Diagnosis 8.3.1.2.2. By Treatment 8.3.1.2.3. By Mode of Administration 8.3.1.2.4. By End User 8.3.2. India Pleurodynia Treatment Market Outlook 8.3.2.1. Market Size & Forecast 8.3.2.1.1. By Value 8.3.2.2. Market Share & Forecast 8.3.2.2.1. By Diagnosis 8.3.2.2.2. By Treatment 8.3.2.2.3. By Mode of Administration 8.3.2.2.4. By End User 8.3.3. Japan Pleurodynia Treatment Market Outlook 8.3.3.1. Market Size & Forecast 8.3.3.1.1. By Value 8.3.3.2. Market Share & Forecast 8.3.3.2.1. By Diagnosis 8.3.3.2.2. By Treatment 8.3.3.2.3. By Mode of Administration 8.3.3.2.4. By End User 8.3.4. South Korea Pleurodynia Treatment Market Outlook 8.3.4.1. Market Size & Forecast 8.3.4.1.1. By Value 8.3.4.2. Market Share & Forecast 8.3.4.2.1. By Diagnosis 8.3.4.2.2. By Treatment 8.3.4.2.3. By Mode of Administration 8.3.4.2.4. By End User 8.3.5. Australia Pleurodynia Treatment Market Outlook 8.3.5.1. Market Size & Forecast 8.3.5.1.1. By Value 8.3.5.2. Market Share & Forecast 8.3.5.2.1. By Diagnosis 8.3.5.2.2. By Treatment 8.3.5.2.3. By Mode of Administration 8.3.5.2.4. By End User 9. South America Pleurodynia Treatment Market Outlook 9.1. Market Size & Forecast 9.1.1. By Value 9.2. Market Share & Forecast 9.2.1. By Diagnosis 9.2.2. By Treatment 9.2.3. By Mode of Administration 9.2.4. By End User 9.2.5. By Country 9.3. South America: Country Analysis 9.3.1. Brazil Pleurodynia Treatment Market Outlook 9.3.1.1. Market Size & Forecast 9.3.1.1.1. By Value 9.3.1.2. Market Share & Forecast 9.3.1.2.1. By Diagnosis 9.3.1.2.2. By Treatment 9.3.1.2.3. By Mode of Administration 9.3.1.2.4. By End User 9.3.2. Argentina Pleurodynia Treatment Market Outlook 9.3.2.1. Market Size & Forecast 9.3.2.1.1. By Value 9.3.2.2. Market Share & Forecast 9.3.2.2.1. By Diagnosis 9.3.2.2.2. By Treatment 9.3.2.2.3. By Mode of Administration 9.3.2.2.4. By End User 9.3.3. Colombia Pleurodynia Treatment Market Outlook 9.3.3.1. Market Size & Forecast 9.3.3.1.1. By Value 9.3.3.2. Market Share & Forecast 9.3.3.2.1. By Diagnosis 9.3.3.2.2. By Treatment 9.3.3.2.3. By Mode of Administration 9.3.3.2.4. By End User 10. Middle East and Africa Pleurodynia Treatment Market Outlook 10.1. Market Size & Forecast 10.1.1. By Value 10.2. Market Share & Forecast 10.2.1. By Diagnosis 10.2.2. By Treatment 10.2.3. By Mode of Administration 10.2.4. By End User 10.2.5. By Country 10.3. MEA: Country Analysis 10.3.1. South Africa Pleurodynia Treatment Market Outlook 10.3.1.1. Market Size & Forecast 10.3.1.1.1. By Value 10.3.1.2. Market Share & Forecast 10.3.1.2.1. By Diagnosis 10.3.1.2.2. By Treatment 10.3.1.2.3. By Mode of Administration 10.3.1.2.4. By End User 10.3.2. Saudi Arabia Pleurodynia Treatment Market Outlook 10.3.2.1. Market Size & Forecast 10.3.2.1.1. By Value 10.3.2.2. Market Share & Forecast 10.3.2.2.1. By Diagnosis 10.3.2.2.2. By Treatment 10.3.2.2.3. By Mode of Administration 10.3.2.2.4. By End User 10.3.3. UAE Pleurodynia Treatment Market Outlook 10.3.3.1. Market Size & Forecast 10.3.3.1.1. By Value 10.3.3.2. Market Share & Forecast 10.3.3.2.1. By Diagnosis 10.3.3.2.2. By Treatment 10.3.3.2.3. By Mode of Administration 10.3.3.2.4. By End User 11. Market Dynamics 11.1. Drivers 11.2. Challenges 12. Market Trends & Developments 12.1. Recent Developments 12.2. Product Launches 12.3. Mergers & Acquisitions 13. Global Pleurodynia Treatment Market: SWOT Analysis 14. Competitive Landscape 14.1. Bristol-Myers Squibb Co 14.1.1. Business Overview 14.1.2. Product & Service Offerings 14.1.3. Recent Developments 14.1.4. Financials (If Listed) 14.1.5. Key Personnel 14.1.6. SWOT Analysis 14.2. F. Hoffmann-La Roche Ltd 14.3. Pfizer Inc 14.4. Sanofi SA 14.5. Johnson & Johnson 14.6. Merck & Co Inc. 14.7. GlaxoSmithKline PLC 14.8. Reckitt Benckiser PLC 14.9. Bayer AG 14.10.Novartis AG 15. Strategic Recommendations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
TechSci Research社のヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD(industry)の最新刊レポート
よくあるご質問TechSci Research社はどのような調査会社ですか?テックサイリサーチ(TechSci Research)は、カナダ、英国、インドに拠点を持ち、化学、IT、環境、消費財と小売、自動車、エネルギーと発電の市場など、多様な産業や地域を対象とした調査・出版活... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|